Rethinking Treg Therapy Design to Incorporate Immune Reset Lymphodepletion & Enhance Self-Renewal & Persistence

11:30 am - Wednesday 24th March 2027

  • Identifying committed Treg precursor populations that may complement conventional Treg therapies to achieve more durable immune tolerance
  • Engineering Tregs to withstand CD3-directed depletion and unlock new conditioning strategies for cell therapy
  • Assessing how evolving standards of care in Type 1 diabetes are reshaping trial design and the positioning of next-generation Treg therapies

Speakers:

Professor
Chicago University Anschutz Division of Hematology